Detection of occult hepatitis C virus infection among Egyptian patients with hepatocellular carcinoma who achieved sustained virologic response to direct-acting antiviral therapy

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Kassem F.E.M.A.; El-Kholy E.E.; Mohamed A.H.; Abdul-Mohaymen A.M.; Gomaa A.I.; Hassan A.S.M.

Journal: Egyptian Pharmaceutical Journal

Publisher: National Information and Documentation Center (NIDOC) Academy of Scientific Research and Technology

Publication Date: 1 April 2025

Volume / Issue: Volume 24 / Issue 2

Pages: 171–180

ISSN: 16874315

DOI: 10.21608/epj.2025.407585

Scopus: View on Scopus

Document Type: Article

Access: All Open Access; Hybrid Gold Open Access


Authors and Affiliations

Kassem F.E.M.A., Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt; El-Kholy E.E., Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; Mohamed A.H., Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt; Abdul-Mohaymen A.M., Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; Gomaa A.I., Department of Tropical Medicine, National Liver Institute, Menoufia University, Menoufia, Egypt; Hassan A.S.M., Department of Electron Microscopy, Theodore Bilharz Research Institute, Giza, Egypt


Abstract

Background Occult hepatitis C virus infection (OCI) is defined as the presence of hepatitis C virus (HCV) RNA in nonserum reservoirs without any detectable HCV-RNA in serum by standard assays. The association between OCI and hepatocellular carcinoma (HCC) is controversial. Direct-acting antiviral (DAA) therapy effectively controls HCV infection and proves sustained virological response (SVR). However, HCC after DAA therapy is debatable. Objective In this study, we tried to detect OCI in HCC Egyptian patients who achieved SVR post-DAA therapy for possible correlation and prediction for HCC. Patients and methods A cross–sectional study included seventy HCC Egyptian patients who achieved SVR post sofosbuvir/daclatasvir (SOF/DACLA) +/–ribavirin therapy. HCV-RNA was detected in peripheral blood mononuclear cells (PBMCs) by RT-PCR. Immune transmission electron microscopy (TEM) was done to study OCI in PBMCs using specific anti-HCV antibodies. Results and conclusion TEM examination revealed positive OCI in PBMCs of all patients (70/70) with 3 stages of grading reflecting viral particle load in PBMCs, with 68.6% of the patients having a marked OCI grade, while PCR only detected 5.7% (4/70) of OCI. Nearly 67.1% of the cases received dual anti-HCV therapy (sofosbuvir/daclatasvir). Ribavirin-inclusive DAA treatment shows a higher grade of OCI (P=0.02). The average duration from SVR to HCC development was 29.8±13.4 months. In conclusion, DAA drugs effectively eliminate HCV in serum, but OCI is still considered a risk for developing HCC, recommending a re-definition for SVR through detecting HCV-RNA in serum, PBMCs, and TEM studies. Our study is the first to provide electron microscopy as a sensitive tool for OCI detection with established superiority over the PCR technique. © 2025 Egyptian Pharmaceutical Journal | Published by NIDOC.


Keywords

direct acting antiviral drugs; hepatocellular carcinoma; immune electron microscopy; occult hepatitis C infection; daclatasvir plus sofosbuvir; ribavirin; virus antibody; virus RNA; adult; antiviral therapy; Article; cancer patient; controlled study; correlation analysis; cross-sectional study; Egyptian; female; hepatitis C; Hepatitis C virus; Hepatitis C virus genotype 4; human; human cell; liver carcinogenesis; liver cell carcinoma; major clinical study; male; nonhuman; peripheral blood mononuclear cell; prediction; real time polymerase chain reaction; sustained virologic response; transmission electron microscopy; virus detection; virus load; virus particle


Citation Information

Scopus Citations: 0


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

Transcriptome analysis for Schistosoma vector snail’s Oncomelania hupensis exposed to silver nanoparticles

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region